Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™ (rhenium Re-186 obisbemeda), is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PSTV | PLUS THERAPEUTICS, INC. | 2025-10-30 19:47:41 | 0.55 | 0.02 | 3.77 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PSTV | 0001095981 | PLUS THERAPEUTICS, INC. | US72941H5090 | — | 330827593 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 4200 MARATHON BLVD. | AUSTIN | TX | 78756 | UNITED STATES | US | 737.255.7194 | 4200 MARATHON BLVD., AUSTIN, TX, 78756 | 4200 MARATHON BLVD., AUSTIN, TX, 78756 | CYTORI THERAPEUTICS, INC. | Biotechnology / Pharmaceuticals | — | — | — | https://plustherapeutics.com/ | 8,200,000 | 92,438,432 | 99,264,526 | Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™ (rhenium Re-186 obisbemeda), is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®. | 2025-10-30 16:36:52 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 8,200,000 | 2,400,000 | 41.3793 | 16,999,626 | 12,723,544 | 297.5515 |
| 2023 | 5,800,000 | -6,300,000 | -52.0661 | 4,276,082 | -30,833,803 | -87.8209 |
| 2022 | 12,100,000 | -18,700,000 | -60.7143 | 35,109,885 | 12,934,860 | 58.3308 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Norman Lafrance | Chief Medical Officer | 2022 | 440,000 | — | — | 152,460 | 45,351 | 637,811 |
| Andrew Sims | Chief Financial Officer | 2022 | 305,000 | — | — | 125,164 | 16,012 | 446,176 |
| Marc H. Hedrick | Chief Executive Officer, President | 2022 | 535,000 | — | — | 361,928 | 57,723 | 954,651 |
| Andrew Sims | Chief Financial Officer | 2021 | 260,000 | — | — | 108,063 | 9,070 | 845,091 |
| Norman Lafrance | Chief Medical Officer | 2021 | 60,077 | — | — | 27,427 | 0 | 292,704 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 21 |
| 2023 | 20 |
| 2022 | 17 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 5,824,000 | 4,913,000 | 224,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 10,580,000 | 9,690,000 | 9,698,000 |
| General And Administrative Expenses | 9,939,000 | 8,544,000 | 10,238,000 |
| Operating Expenses | 20,519,000 | 18,234,000 | 19,936,000 |
| Operating Income | -14,695,000 | -13,321,000 | -19,712,000 |
| Net Income | -12,978,000 | -13,316,000 | -20,275,000 |
| Earnings Per Share Basic | -1.95 | -4.24 | -0.77 |
| Earnings Per Share Diluted | -2.34 | -4.24 | -0.77 |
| Weighted Average Shares Outstanding Basic | 6,640,251 | 3,140,925 | 26,255,256 |
| Weighted Average Shares Outstanding Diluted | 7,700,774 | 3,140,925 | 26,255,256 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 76,000 | 8,554,000 | 18,120,000 |
| Marketable Securities Current | 3,530,000 | — | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,082,000 | 1,280,000 | 3,697,000 |
| Total Assets Current | 5,259,000 | 9,834,000 | 21,817,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 448,000 | 906,000 | 1,324,000 |
| Other Assets Non Current | 12,000 | 32,000 | 12,000 |
| Total Assets Non Current | 1,374,000 | 1,554,000 | 2,050,000 |
| Total Assets | 6,633,000 | 11,388,000 | 23,867,000 |
| Accounts Payable | 9,474,000 | 4,758,000 | 8,364,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 3,292,000 | 3,976,000 | 1,608,000 |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 15,551,000 | 10,727,000 | 11,852,000 |
| Long Term Debt | — | — | 3,786,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 31,000 | 2,009,000 | 5,570,000 |
| Total Liabilities | 15,582,000 | 12,736,000 | 17,422,000 |
| Common Stock | 6,000 | 5,000 | 34,000 |
| Retained Earnings | -493,479,000 | -480,501,000 | -467,185,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | -8,949,000 | -1,348,000 | 6,445,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 723,000 | 628,000 | 619,000 |
| Share Based Compensation Expense | 550,000 | 569,000 | 606,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 4,702,000 | -3,677,000 | 6,452,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -10,554,000 | -12,851,000 | -12,972,000 |
| Purchases Of Marketable Securities | 15,590,000 | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 146,000 | — | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -4,111,000 | -160,000 | -759,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | 5,527,000 | 15,059,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 3,996,000 | 1,608,000 | 1,608,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 6,187,000 | 3,445,000 | 13,451,000 |
| Change In Cash | -8,478,000 | -9,566,000 | -280,000 |
| Cash At End Of Period | 76,000 | 8,554,000 | 18,120,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 32,000 | 222,000 | 327,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -1.95 | -4.24 | -0.77 |
| Price To Earnings Ratio | -0.5897 | -0.4128 | -0.4117 |
| Earnings Growth Rate | -54.0094 | 450.6494 | — |
| Price Earnings To Growth Ratio | 0.0109 | -0.0009 | — |
| Book Value Per Share | -1.3477 | -0.4292 | 0.2455 |
| Price To Book Ratio | -0.8533 | -4.0778 | 1.2914 |
| Ebitda | -12,076,000 | -12,293,000 | -18,945,000 |
| Enterprise Value | — | — | -4,403,083.848 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | 0.8369 |
| Capital Expenditures | 265,000 | 210,000 | 466,000 |
| Free Cash Flow | -10,819,000 | -13,061,000 | -13,438,000 |
| Return On Equity | 1.4502 | 9.8783 | -3.1458 |
| One Year Beta | 0.9069 | -0.5016 | 0.8713 |
| Three Year Beta | 0.7104 | 0.8111 | 1.1997 |
| Five Year Beta | 1.066 | 1.2111 | 1.2795 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Sims Andrew John Hugh MacIntyre | Chief Financial Officer | 2025-10-01 | 38,323 | A | 48,138 |
| Sims Andrew John Hugh MacIntyre | Chief Financial Officer | 2025-10-01 | 38,323 | D | 421,555 |
| HEDRICK MARC H | Director, Chief Executive Officer | 2025-10-01 | 159,681 | A | 180,106 |
| HEDRICK MARC H | Director, Chief Executive Officer | 2025-10-01 | 159,681 | D | 1,756,487 |
| Lenk Robert P | Director | 2025-08-22 | 110,000 | A | 139,327 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| DAGCO, INC. | 2025-09-30 | 17,696 | 25,882 | 0.6837 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 45 | 133 | 0.3383 |
| Tower Research Capital LLC (TRC) | 2025-06-30 | 2,102 | 6,045 | 0.3477 |
| MILLENNIUM MANAGEMENT LLC | 2025-06-30 | 8,428 | 24,233 | 0.3478 |
| JANE STREET GROUP, LLC | 2025-06-30 | 40,851 | 117,454 | 0.3478 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 8,280 | 3,775.68 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 5,315 | 2,423.64 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Extended Market Index Fund | FSMAX | 83,439 | 38,048.18 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Select Shares | VSEMX | 32,541 | 11,317.76 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Plus Shares | VEMPX | 32,541 | 11,317.76 | 0.0 |